PURPOSE: To evaluate the feasibility of 1-(4-amino- 2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) of pre-treated procarbazine for elderly patients with newly diagnosed glioblastomas. PATIENTS AND METHODS: From January 2004 to March 2005, 7 patients with glioblastoma were enrolled. After maximal surgical resection, patients were treated with two to four cycles of procarbazine (100 mg/m(2) for day 1 to 5), ACNU (80 mg/m(2)/day(1) for day 5), cepharantine (70 mg for day 5 and 12) and vincristine (1.4 mg/m(2) for day 5 and 12). RESULTS: Significant toxicities of this regimen, including infectious toxicities, are described. Among the 7 patients enrolled, there were 6 patients were died, and one was still alive with disease at 13 months. The 6-month progression-free survival and 1-year overall survival are 29% (95% CI, 16% to 73%) and 29% (95% CI, 16% to 73%), respectively. CONCLUSION: The chemotherapy regimen is active but too toxic for elderly patients with newly diagnosed glioblastoma.
PURPOSE: To evaluate the feasibility of 1-(4-amino- 2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) of pre-treated procarbazine for elderly patients with newly diagnosed glioblastomas. PATIENTS AND METHODS: From January 2004 to March 2005, 7 patients with glioblastoma were enrolled. After maximal surgical resection, patients were treated with two to four cycles of procarbazine (100 mg/m(2) for day 1 to 5), ACNU (80 mg/m(2)/day(1) for day 5), cepharantine (70 mg for day 5 and 12) and vincristine (1.4 mg/m(2) for day 5 and 12). RESULTS: Significant toxicities of this regimen, including infectious toxicities, are described. Among the 7 patients enrolled, there were 6 patients were died, and one was still alive with disease at 13 months. The 6-month progression-free survival and 1-year overall survival are 29% (95% CI, 16% to 73%) and 29% (95% CI, 16% to 73%), respectively. CONCLUSION: The chemotherapy regimen is active but too toxic for elderly patients with newly diagnosed glioblastoma.
Authors: D S Mohan; J H Suh; J L Phan; P A Kupelian; B H Cohen; G H Barnett Journal: Int J Radiat Oncol Biol Phys Date: 1998-12-01 Impact factor: 7.038
Authors: J Y Pierga; K Hoang-Xuan; L Feuvret; J M Simon; P Cornu; F Baillet; J J Mazeron; J Y Delattre Journal: J Neurooncol Date: 1999-06 Impact factor: 4.130
Authors: Mark R Gilbert; Henry S Friedman; John F Kuttesch; Michael D Prados; Jeffrey J Olson; Gregory H Reaman; Sara L Zaknoen Journal: Neuro Oncol Date: 2002-10 Impact factor: 12.300
Authors: M Hirai; K Tanaka; T Shimizu; Y Tanigawara; M Yasuhara; R Hori; Y Kakehi; O Yoshida; K Ueda; T Komano Journal: J Pharmacol Exp Ther Date: 1995-10 Impact factor: 4.030